NLRP3 and colitis: Additionally, the findings by Saber et al. (2021) highlights the potential of combined treatment of a P2X7R blocker with other antagonists of molecules involved in the inflammatory process since the combination of BBG and OLT1177, an NLRP3 inhibitor, was more effective at protecting against DSS-induced colitis than their individual administration.